Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study Meeting Abstract
| Authors: | Shore, N. D.; Sieber, P. R.; Gleave, M.; De Giorgi, U.; Mehlhaff, B. A.; Danila, D. C.; Dunshee, C.; Lallas, C. D.; Pliskin, M.; Tang, Y.; Haas, G. P.; Rosales, M.; Tarazi, J. C. C.; Zohren, F.; Russell, D.; Freedland, S. J. |
| Abstract Title: | Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Keywords: | 613-135-2370-7650-2454-5112; 613-615-646-3281-7408-2638; 613-4678-146-349 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900023 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.15 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 15 -- Source: Wos |
